'Breakthrough' Lung Cancer Drug Found Effective in Trials

Thursday, 27 Mar 2014 12:26 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Novartis said late on Wednesday that a majority of patients given a development drug against non-small cell lung cancer had responded to the treatment, according to study results published in the New England Journal of Medicine.
The Basel-based drugmaker's LDK378 has been declared a "breakthrough therapy", a designation created by the U.S. Food and Drug Administration in 2012 to help speed drugs to market that treat serious or life-threatening conditions and are deemed likely to work better than existing treatments.
Editor's Note: Knowing these 5 cancer-causing signs is crucial to remaining cancer-free for life

Non-small cell lung cancer is the most common type of lung cancer, and sufferers tend to be non-smokers and younger than other lung cancer patients.
Patients survived for an average of seven months after taking LDK378, and 58 percent of those treated with the drug responded, Novartis said. Novartis is currently conducting Phase II and Phase III trials of the treatment.
The company, which said in January that it had filed for regulatory approval of the drug, said the data formed the basis for its submission.
Novartis, which considers the treatment among the most promising in its pipeline, is facing a "patent cliff" - where a number of best-selling drugs lose market exclusivity.
The company is pinning its hopes on what it hopes will be 'blockbuster' treatments for cancer, heart failure and lung disease. 
Editor's Note: Knowing these 5 cancer-causing signs is crucial to remaining cancer-free for life


© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved